Plasma concentrations of type II phospholipase A2, cytokines and eicosanoids in patients with burns. 1995

H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
Critical Care and Emergency Center, Iwate Medical University, Morioka, Japan.

The plasma concentrations of type II phospholipase A2 (type II PLA2) and eicosanoids, such as leukotriene B4 (LTB4), 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), and thromboxane B2 (TXB2), were determined by radioimmunoassay in 23 patients with burns covering at least 20 per cent of their body surface. Cytokines such as tumour necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6) and interleukin 8 (IL-8) were determined by enzyme-immunosorbent assay. There was no increase in type II PLA2 concentration in the early stage of burns, but an increase in type II PLA2 concentration was triggered by infection (P < 0.0001). The level of type II PLA2 was significantly higher in the non-surviving group than in the surviving group (P = 0.0006), suggesting that it reflects the severity of the disease. There was a significant correlation between the maximum level of type II PLA2 and TNF-alpha (r = 0.6346, P = 0.0011). There was a significant correlation between the maximum level of type II PLA2 and the accompanying plasma concentrations of LTB4, 6-keto-PGF1 alpha, and TXB2 throughout the observation period (r = 0.4814, P = 0.0200; r = 0.5943, P = 0.0028; r = 0.4368, P = 0.0372 respectively). Plasma levels of LTB4, and TXB2 were significantly higher in the burn patients who died than in those who survived (P = 0.0493; P = 0.0493 respectively).

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010741 Phospholipases A Phospholipases that hydrolyze one of the acyl groups of phosphoglycerides or glycerophosphatidates.
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002056 Burns Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like. Burn
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
January 2001, Research communications in molecular pathology and pharmacology,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
November 2009, European heart journal,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
January 1993, Andrologia,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
March 1995, American journal of obstetrics and gynecology,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
October 2000, The American journal of cardiology,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
June 2015, Clinica chimica acta; international journal of clinical chemistry,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
September 2006, Zhonghua xin xue guan bing za zhi,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
April 1997, The Journal of endocrinology,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
February 1993, The Journal of rheumatology,
H Nakae, and S Endo, and K Inada, and H Yamashita, and Y Yamada, and T Takakuwa, and T Kasai, and M Ogawa, and K Uchida
January 1993, European journal of haematology,
Copied contents to your clipboard!